Skip to main content
Fig. 4 | Molecular Neurodegeneration

Fig. 4

From: CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice

Fig. 4

MVC abrogated HIV-induced BBB alterations. Expression of brain endothelial tight junction proteins claudin-5 (a-d), ZO-1 (e-h), and ZO-2 (i-l) were analyzed by immunohistochemistry (a, b) or immunofluorescence (e, f, i, j) with DAPI (blue) for nuclear counterstaining. Metamorph software was used to quantify claudin-5 (b), ZO-1 (f), and ZO-2 (j) levels in all samples; for each sample, 10 random FOV (from the somatosensory cortex) were analyzed. Western blot analyses (c, g, k) and densitometry quantification normalized to sample’s β-actin levels (d, h, l) were also used to quantify claudin-5 (c, d), ZO-1 (g, h), and ZO-2 (k, l) levels in samples. For panels a, e, and i, images were at 40X. The four animal groups included PBS, HIV, HIV + MVC, and MVC; 9 to 11 animals in each group. #P < 0.0001, ***P < 0.0005, **P < 0.006, *P < 0.05. Error bars represent SD

Back to article page